The product specific information for the COVID-19 vaccines available in BC can be found in Part 4: Biological Products, COVID-19 Vaccines.

<table>
<thead>
<tr>
<th>Primary Series</th>
<th>Eligibility Criteria</th>
<th>Number of Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Eligibility Criteria</strong></td>
<td><strong>Number of Doses</strong></td>
<td><strong>Note</strong></td>
</tr>
<tr>
<td><strong>Pediatric population 6 months-4 years of age (inclusive)</strong></td>
<td>2 doses of Moderna: 0.25 mL (25 mcg) – preferred OR 3 doses of Pfizer: 0.2 mL (3 mcg)</td>
<td></td>
</tr>
<tr>
<td><strong>Pediatric population 5-11 years of age (inclusive)</strong></td>
<td>2 doses: Pfizer: 0.2 mL (10 mcg) – preferred OR Moderna: 0.25 mL (50 mcg) – only for those 6-11 years of age</td>
<td></td>
</tr>
<tr>
<td><strong>General population 12 years of age and older</strong></td>
<td>2 doses of any: Pfizer: 0.3 mL (30 mcg) - preferred for 12-29 year olds OR Moderna: 0.5 mL (100 mcg) OR Novavax (≥ 18 years of age): 0.5 mL</td>
<td></td>
</tr>
<tr>
<td><strong>Moderately to severely immunosuppressed (see Appendix B) 6 months-4 years of age</strong></td>
<td>3 doses of Moderna: 0.25 mL (25 mcg) – preferred OR 4 doses of Pfizer: 0.2 mL (3 mcg)</td>
<td></td>
</tr>
<tr>
<td><strong>Moderately to severely immunosuppressed (see Appendix B) 5-11 years of age</strong></td>
<td>3 doses: Pfizer: 0.2 mL (10 mcg) OR Moderna: 0.25 mL (50 mcg) – only for those 6-11 years of age</td>
<td></td>
</tr>
<tr>
<td><strong>Moderately to severely immunosuppressed (see Appendix A) 12 years of age and older</strong></td>
<td>3 doses of any: Moderna: 0.5 mL (100 mcg) - preferred OR Pfizer: 0.3 mL (30 mcg) OR Novavax (≥ 18 years of age): 0.5 mL</td>
<td></td>
</tr>
<tr>
<td><strong>Fall 2022 Booster Dose C, D, E</strong></td>
<td>1 dose – at least 6 months after the primary series: Pfizer (monovalent): 0.2 mL (10 mcg)</td>
<td></td>
</tr>
<tr>
<td><strong>Individuals 5-11 years of age</strong></td>
<td>1 dose – at least 6 months after the primary series or a previous booster dose: Pfizer Bivalent: 0.3 mL (30 mcg) OR Moderna Bivalent: 0.5 mL (50 mcg) – recommended and preferred only for those who are moderately to severely immunosuppressed (see Appendix A)</td>
<td></td>
</tr>
<tr>
<td><strong>Individuals 12-17 years of age</strong></td>
<td>1 dose – at least 6 months after the primary series or a previous booster dose: Pfizer Bivalent: 0.3 mL (30 mcg) OR Moderna Bivalent: 0.5 mL (50 mcg) - preferred for those who are moderately to severely immunosuppressed (see Appendix A)</td>
<td></td>
</tr>
<tr>
<td><strong>Individuals 18 years of age and older</strong></td>
<td>1 dose – at least 6 months after the primary series or a previous booster dose: Pfizer Bivalent: 0.3 mL (30 mcg) OR Moderna Bivalent: 0.5 mL (50 mcg)</td>
<td></td>
</tr>
</tbody>
</table>

---

**A** All doses of COVID-19 vaccine in the primary series are provided as monovalent products. 

**B** mRNA vaccines are the preferred COVID-19 vaccines due to the demonstrated high efficacy and effectiveness with longer term safety data. Novavax COVID-19 vaccine may be offered to individuals for whom COVID-19 mRNA vaccines are contraindicated or have been refused. Janssen COVID-19 vaccine should only be considered when all other authorized COVID-19 vaccines are contraindicated or refused, due to the reduced effectiveness and the possible adverse effects associated with this vaccine (e.g., Thrombosis with Thrombocytopenia Syndrome). 

**C** A fall booster dose is recommended for all individuals 5 years of age and older, at a recommended interval of 6 months (minimum interval of 3 months). For those 12 years of age and older, the fall booster dose should be offered regardless of the number of booster doses previously received. Individuals who received a single dose of Janssen vaccine may receive a booster dose at least 8 weeks later. 

**D** Includes individuals who are moderately to severely immunosuppressed and received an additional dose in the primary series. 

**E** A booster dose is strongly recommended for individuals 65 years of age and older, and those 5 years of age and older who are at higher risk of severe illness due to COVID-19. 

**F** A bivalent COVID-19 mRNA vaccine is recommended for the fall booster dose, however a monovalent product can be provided if a bivalent product is not available, or upon client request.
Appendix A

For those 12 years of age and older, moderately to severely immunosuppressed includes those who:

- Have had a solid organ transplant and are taking immunosuppressive therapy (heart, lung, liver, kidney, pancreas or islet cells, bowel or combination organ transplant).
- Will have, are having, or are on active treatment for solid tumour or haematologic malignancies (like myeloma or leukemia):
  - Will have, are having, or in the last 12 months have received systemic treatment for a haematological malignancy, or in the last 24 months have received anti-CD20 or other B-cell depleting therapies for a haematological malignancy.
  - Will have, are having, or in the last 24 months have had a bone marrow, stem cell transplant or CAR-T or who are still taking immunosuppressive drugs.
  - Will have, are having, or in the last 6 months have received anti-cancer systemic therapy for solid tumours (including but not limited to cytotoxic chemotherapy; molecular targeted therapy; immunotherapy; monoclonal antibodies; bone modifying agents used in the setting of metastatic disease; high dose steroids e.g., equivalent to > 20 mg/day for more than 1 month but excluding patients only receiving hormonal or bone modifying therapy in the adjuvant setting).
  - Are planned for radiation, are having or will have had radiation in the last 3 months.
  - Have a diagnosis of CLL/SLL, myeloma/plasmacytoma, or low grade lymphoma.
- Prior AIDS defining illness or prior CD4 count ≤ 200/mm³ or prior CD4 fraction ≤ 15% or any detectable plasma viral load since January 2021 or HIV infection and ≥ 65 years old or perinatally acquired HIV infection.
- Are on active treatment with the following categories of immunosuppressive therapies:
  - In the last 2 years, been treated with anti-CD20 agents, B-cell depleting agents or similar therapeutic agents.
  - In the last 3 months, been treated with biologic agents that are significantly immunosuppressive, oral immune-suppressing drugs, steroids (orally or by injection >14 days), immune-suppressing infusions/injections or intermittent high dose steroids administered as immune suppression prior to intravenous enzyme replacement treatment.
- Have combined immune deficiencies affecting T-cells, immune dysregulation (particularly familial hemophagocytic lymphohistiocytosis) or those with type 1 interferon defects (caused by a genetic primary immunodeficiency disorder or secondary to anti-interferon autoantibodies).
- Have a moderate to severe primary immunodeficiency which has been diagnosed by an adult or pediatric immunologist and requires ongoing immunoglobulin replacement therapy (IVIG or SCIG) or the primary immunodeficiency has a confirmed genetic cause (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome).
- On dialysis (hemodialysis or peritoneal dialysis) or have stage 5 chronic kidney disease (eGFR <15 mL/min) or have glomerulonephritis and receiving steroid treatment.

Appendix B

For children 6 months to 11 years of age, moderately to severely immunosuppressed includes those who:

- Have had a solid organ transplant (heart, lung, liver, kidney, pancreas or islet cells, bowel or combination organ transplant).
- In the last year, received systemic treatment for a haematological malignancy, including anti-CD20 or other B-cell depleting therapies.
- In the last 2 years, have had a bone marrow, stem cell transplant, CAR-T, or is still taking immunosuppressant medications.
- In the last 6 months have received anti-cancer systemic therapy for solid tumors (including but not limited to: cytotoxic chemotherapy, molecular targeted therapy, immunotherapy, monoclonal antibodies, bone modifying agents used in the setting of metastatic disease, high dose steroids [e.g. equivalent of > 20 mg/day for more than 1 month but excluding patients only receiving hormonal or bone modifying therapy in the adjuvant setting]).
- In the last 3 months, have received or are receiving radiation therapy for cancer.

A list of these medications can be found on the government of B.C. website under “People who are moderately to severely immunocompromised.”
• In the past year, have received anti-CD20, B-cell depleting or similar agents. H
• In the last 3 months, received immunosuppressing therapies including biologic agents, oral-immune suppressing drugs, steroids (orally or by injection for a period of > 14 days), immune suppressing infusions/injections or intermittent high dose steroids administered as immune suppression prior to intravenous enzyme replacement treatment. H
• On dialysis (hemodialysis or peritoneal dialysis) or have stage 5 chronic kidney disease (eGFR <15 mL/min) or have glomerulonephritis and receiving steroid treatment.
• Have a primary immunodeficiency which has been diagnosed by a pediatric immunologist.
• Prior AIDS defining illness or HIV infection with prior CD4 count ≤ 200/mm$^3$, prior CD4 ≤ 15% or detectable plasma viral load in the last year.

H A list of these medications can be found on the government of B.C. website under “My child is moderately to severely immunocompromised".